Caprico Biotech and Mindray Enter Strategic Collaboration to Advance High-Quality Development of Flow Cytometry Diagnostics

On the afternoon of September 5, Caprico Biotechnologies (hereinafter referred to as “Caprico”) and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (hereinafter referred to as “Mindray”) held a strategic cooperation signing ceremony at the Mindray Base in Beijing.

Both parties will leverage their complementary product portfolios to achieve win-win cooperation, strengthen research in the clinical flow cytometry field, and drive high-quality development in the flow cytometry sector by leveraging technological innovations in algorithms, automation, and intelligence.

Chairman of Caprico BiotechnologiesWang Hui, Vice ChairmanLi RunzhaoDeputy General Manager of SalesBai Xiaojie, Deputy General Manager of BusinessGuo XinManager, Clinical Application R&D DepartmentChen Xin; General Manager, Mindray Beijing Research InstituteGuo Wenheng, Instrument Department ManagerLi XinReagent Department ManagerGong XinFlow Cytometry Product Marketing ManagerCheng Yi, Flow Cytometry Product ManagerWang Tengfeiattended the signing ceremony.

Wang Hui, Chairman of Caprico Biotechnologies, stated that the collaboration between Mindray and Caprico represents a milestone in the industry. Moving forward, both parties will focus their cooperation on key areas, fostering mutual learning, appreciation, and respect, ultimately achieving shared success. He expressed confidence that their joint efforts will make greater contributions to the advancement of the entire industry and create greater value.

Guo Wenheng, General Manager of Mindray’s Beijing Research Institute, stated that Mindray has a long-term development plan for its flow cytometry business. The collaboration between the two parties is based on product complementarity. Through this partnership, Mindray aims to strengthen research in the clinical applications of flow cytometry, leverage technological innovations in algorithms, automation, and intelligence to further address clinical pain points, explore new market opportunities, and promote high-quality development in the field of flow cytometry.

Caprico Biotechnologies has been deeply engaged in the field of flow cytometry antibodies for over a decade, possessing core capabilities in hybridoma cell line development, flow antibody purification and preparation, fluorescent dye conjugation, and production quality control of flow cytometry antibody reagents. The quantity and quality of the hybridoma cell line raw materials and flow cytometry antibody reagents developed by the company are at an internationally leading level. The company has obtained ISO 13485 quality management system certification, and all its products have completed FDA registration. Caprico Biotechnologies offers a comprehensive portfolio of flow cytometry antibodies with complete regulatory approvals, providing high-quality products and professional services. By establishing an academic platform for flow cytometry, the company continues to create value for its customers.

Mindray has been deeply engaged in the field of in vitro diagnostics for over 20 years, covering nine major areas: hematology, clinical chemistry, immunoassay, coagulation, urinalysis, microbiology, HbA1c, flow cytometry, and molecular diagnostics. Through continuous R&D innovation, Mindray delivers high-quality products to more than 70,000 medical institutions across China.

In 2014, Mindray launched its first clinical-grade flow cytometer, the BriCyte E6. Its features of “ease, intelligence, speed, and simplicity” shattered customers’ traditional perceptions of flow cytometry usage, offering a refreshing experience. Over the past decade since its market launch, the BriCyte E6 has earned a strong reputation and gained widespread trust among customers for its stable performance, accurate result output, and efficient automation experience.

After a decade of accumulation and in-depth research, Mindray launched the new-generation BriCyte M series flow cytometers in July 2024. The series includes the clinical models BriCyte MX and BriCyte MC, as well as the research model BriCyte MS, featuring comprehensive upgrades in configuration and performance to deliver a more flexible, stable, intelligent, and efficient experience for customers.

New-Generation Flow Cytometer: BriCyte M Series

At the event, both parties engaged in extensive exchanges and discussions regarding this strategic cooperation. They reached a consensus to implement comprehensive strategic collaboration in the field of flow cytometry testing, spanning research and development, production, manufacturing, and sales. By fully leveraging their respective technical advantages, the parties aim to further enhance overall operational efficiency, achieve mutual benefits, complement each other’s strengths, and foster common development.

Meanwhile, both parties are committed to jointly developing richer and more convenient flow cytometry testing solutions, providing hospitals, patients, and the entire flow cytometry industry with more comprehensive and high-quality services, enabling more people to benefit from premium life care.